5月21日 - ** 生物科技公司Moderna（MRNA.O）的股价在早盘交易中下跌3%，至46.70美元
**美国食品药品监督管理局（FDA） 表示，将召开一次由外部专家组成的会议(link)，以评估莫德纳的实验性流感疫苗
** 咨询委员会会议定于6月 18日举行
** FDA 此前曾一度驳回该公司基于mRNA技术的季节性流感疫苗申请，但随后改变立场(link)，决定审议其修订后的申请
** 预计该机构将于8月5日前作出决定
** 计入此次会议消息，该公司股价年内累计上涨58.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.